Biotechs' financing deals help with development costs

05/8/2006 | American City Business Journals

Biotechnology companies already burdened with funding treatments nearing market approval are entering into agreements with private-equity firms to create separate entities to help shoulder the risk and cost associated with developing promising early-stage drugs. This financing mechanism fell out of favor amid some scandals involving off-balance sheet arrangements, but the new deals are transparent and the entities' financial dealings are covered in the parent company's statements.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA